A stroke does not directly cause the most common forms of glaucoma, but the two conditions are connected through overlapping vascular disease in ways that matter for anyone dealing with either diagnosis. The same narrowed arteries that set the stage for a brain stroke can starve the eye of blood and trigger a particularly aggressive form of glaucoma. And after a stroke damages the brain’s visual processing areas, the retinal nerve cells that no longer have a downstream partner can slowly waste away in a process that mimics glaucoma-like damage. The relationship runs in both directions, shares root causes, and has practical consequences for treatment.
The Vascular Pipeline That Feeds Both the Brain and the Eye
Your brain and your eyes get their blood supply from the same source: the internal carotid arteries. When atherosclerosis narrows those arteries, both organs are at risk. Severe carotid stenosis is a well-known cause of ischemic stroke, but it also starves the eye, producing a condition called ocular ischemic syndrome. This syndrome is rare, but when it develops, it can lead directly to neovascular glaucoma, one of the most sight-threatening forms of the disease.1PubMed Central. Ocular ischemic syndrome – a systematic review
In a study of patients with ocular ischemic syndrome, neovascular glaucoma developed in the majority of affected eyes, with the degree of carotid artery narrowing on the same side identified as a significant risk factor.2PubMed Central. Clinical Features of Ocular Ischemic Syndrome and Risk Factors for Neovascular Glaucoma What this means in practice is that the same atherosclerotic plaque threatening a stroke on one side of the neck can simultaneously be cutting off blood flow to the eye on that same side. A patient presenting with neovascular glaucoma and no obvious diabetic eye disease should have their carotid arteries checked, because the underlying blockage carries stroke risk too.
How Ischemia Triggers Neovascular Glaucoma
Neovascular glaucoma is different from the far more common open-angle glaucoma. It occurs when abnormal new blood vessels grow across the iris and into the eye’s drainage angle, blocking the outflow of fluid and spiking eye pressure. The root cause is usually severe oxygen deprivation in the retina.3PubMed Central. Etiology, pathogenesis, and diagnosis of neovascular glaucoma When retinal cells are starved of oxygen, they release a signaling molecule called vascular endothelial growth factor, or VEGF, which tells the body to grow new blood vessels. The problem is that these emergency vessels are fragile and grow in the wrong places.4PubMed. Vascular endothelial growth factor upregulation in human central retinal vein occlusion
The most common triggers for this chain of events are diabetic retinopathy and central retinal vein occlusion, but ocular ischemic syndrome from carotid disease is another major one. Since carotid disease also causes strokes, a stroke and neovascular glaucoma can share the same upstream cause even though the stroke does not cause the glaucoma directly. They are more like siblings born of the same parent disease than parent and child.
What Happens to the Retina After a Brain Stroke
There is, however, a more direct route from stroke to eye damage that looks a lot like glaucoma under examination. When a stroke destroys part of the visual cortex at the back of the brain, the retinal ganglion cells that were sending signals to that area lose their downstream target. Over time, those disconnected cells degenerate and die in a process called retrograde trans-synaptic degeneration.5PubMed Central. Survival of retinal ganglion cells after damage to the occipital lobe in humans is activity dependent
Research using advanced eye imaging has shown that in areas of the visual field left permanently blind by a stroke, the retinal ganglion cell layer thins over time. The degree of thinning depends on how much residual activity remains in the damaged visual cortex. More activity in the surviving brain tissue was associated with less ganglion cell loss, suggesting that keeping those neural circuits active offers some protection.5PubMed Central. Survival of retinal ganglion cells after damage to the occipital lobe in humans is activity dependent
This retinal thinning is structurally similar to what happens in glaucoma, where retinal ganglion cells also die off progressively. It is not glaucoma in the clinical sense, because the eye pressure is usually normal and the mechanism is entirely different. But it can confuse diagnostic testing. An ophthalmologist measuring retinal nerve fiber layer thickness on a stroke patient might see thinning and wonder whether the patient has early glaucoma, when in reality the damage originated in the brain. Distinguishing between the two requires careful correlation with the patient’s visual field deficits and stroke history.
Normal-Tension Glaucoma and Silent Strokes
Normal-tension glaucoma is a form of the disease where the optic nerve deteriorates even though eye pressure stays within the statistically normal range. It has long puzzled clinicians, and one line of investigation has focused on small, silent strokes in the brain as a possible contributing factor. These are tiny areas of dead brain tissue visible on MRI that the patient never noticed because they did not cause obvious symptoms.
In one study of patients with normal-tension glaucoma, about a third showed signs of ischemic changes on brain MRI.6PubMed. Visual field damage in normal-tension glaucoma patients with or without ischemic changes in cerebral magnetic resonance imaging Another study found that patients whose visual fields worsened over time were roughly twice as likely to have silent cerebral infarcts compared to patients whose fields remained stable.7PubMed. Silent cerebral infarct and visual field progression in newly diagnosed normal-tension glaucoma: a cohort study The implication is that the same small-vessel vascular disease chipping away at brain tissue may also be compromising blood flow to the optic nerve.
This does not mean silent strokes cause normal-tension glaucoma outright. But it suggests that in some patients, the disease is more vascular in nature than previously appreciated. For those patients, managing blood pressure and other cardiovascular risk factors might matter as much as managing eye pressure.
The Role of Blood Pressure Drops at Night
One specific vascular mechanism that links stroke risk and glaucoma progression is nocturnal hypotension, the drop in blood pressure that occurs during sleep. Everyone’s blood pressure falls at night, but in some people, especially those taking blood pressure medications, the drop is excessive. Research has shown that patients with normal-tension glaucoma had significantly greater nighttime drops in diastolic blood pressure, and that this nocturnal dipping was associated with progressive visual field loss.8PubMed. Nocturnal arterial hypotension and its role in optic nerve head and ocular ischemic disorders
The logic is straightforward: the optic nerve head needs a steady blood supply. If blood pressure plunges during sleep while eye pressure stays the same, the perfusion pressure pushing blood through the optic nerve drops below a critical threshold. The same nighttime blood pressure dips are a known risk factor for stroke in vulnerable populations. So an overly aggressive blood pressure treatment regimen could, in theory, worsen both stroke risk in the brain and ischemic damage at the optic nerve simultaneously. This is one reason why ophthalmologists and cardiologists sometimes need to coordinate care for patients with both conditions.
Shared Genetic Vulnerability
The overlap between glaucoma and stroke goes beyond just shared risk factors like high blood pressure and diabetes. Genetic research has identified specific genes that appear to contribute to both conditions. A recent study using combined genetic analysis methods found three genes that may play a role in how primary open-angle glaucoma increases the risk of ischemic stroke.9Briefings in Bioinformatics. Integrative genetic analysis reveals new relationships between intraocular pressure, glaucoma, and ischemic stroke risk: a study based on combined SNP-to-gene, Mendelian randomization and pathway investigations Two of these genes are well known in glaucoma genetics and are also implicated in cardiovascular disease pathways.
A meta-analysis pooling data from multiple studies found that people with glaucoma had roughly double the odds of experiencing a stroke compared to those without the eye disease.10PubMed Central. Association between glaucoma and risk of stroke: A systematic review and meta-analysis A separate long-term cohort study following patients with open-angle glaucoma over a decade found a more modest but still statistically significant increase in stroke incidence, with older adults and men facing higher risk.11PubMed. Increased stroke risk among patients with open-angle glaucoma: a 10-year follow-up cohort study The size difference between these estimates likely reflects different study designs and populations, but the direction of the association is consistent: having glaucoma seems to signal elevated cerebrovascular risk.
This is worth knowing because glaucoma is far more commonly diagnosed than stroke is predicted. If your ophthalmologist identifies glaucoma, it may be reasonable to take a closer look at your overall cardiovascular health, not just your eyes.
Endothelial Dysfunction as the Common Thread
Underlying much of this overlap is dysfunction in the endothelium, the thin layer of cells lining every blood vessel in the body. When endothelial cells stop working properly, blood vessels lose their ability to dilate on demand, become more prone to inflammation, and accelerate the buildup of atherosclerotic plaque. This process begins years before it produces symptoms and eventually leads to heart attacks, strokes, and other vascular catastrophes.12European Heart Journal. The eye and the heart
The eye’s blood vessels are not exempt. In fact, because the retinal and optic nerve blood vessels are among the smallest in the body, they may be among the first to show the effects of endothelial dysfunction. The same process that will eventually narrow a carotid artery enough to cause a stroke is, decades earlier, reducing the tiny vessels’ ability to deliver adequate blood to the optic nerve. That is one reason why eye exams can sometimes reveal vascular risk that standard blood tests miss.
Retinal Artery Occlusion as a Stroke Warning
There is also a condition sometimes called an “eye stroke” that deserves mention here because it is often confused with glaucoma-related vision loss but carries very different implications. Central retinal artery occlusion, or CRAO, occurs when a clot blocks the main artery feeding the retina, causing sudden, painless vision loss. The American Heart Association classifies CRAO as a form of acute ischemic stroke.13PubMed. Management of Central Retinal Artery Occlusion: A Scientific Statement From the American Heart Association
A meta-analysis found that about 30% of patients with acute central retinal artery occlusion had evidence of a simultaneous silent brain stroke on MRI.14PubMed Central. Risk of acute stroke in patients with retinal artery occlusion: a systematic review and meta-analysis This high rate is why current guidelines recommend urgent neurological evaluation for anyone who experiences sudden retinal artery blockage. The eye event is essentially an early alarm for the brain. While this is not glaucoma, it illustrates how closely the vascular fates of the eye and brain are linked, and how an acute eye event can signal imminent stroke risk.
Unusual Vascular Causes of Glaucoma After Stroke-Like Events
Rarer vascular abnormalities can also produce glaucoma through mechanisms quite different from those described above. A carotid cavernous fistula, an abnormal connection between the carotid artery and the venous sinus cavity behind the eye, can raise venous pressure in the eye dramatically. One case report documented eye pressures climbing to 34 mm Hg on the affected side, well into the glaucoma range. After the fistula was closed by threading a catheter through the artery, pressure dropped back to 19 mm Hg within a week.15PubMed Central. Glaucoma Management in Carotid Cavernous Fistula Carotid cavernous fistulas can result from trauma or from spontaneous rupture, and they sometimes coexist with or mimic stroke-like symptoms such as double vision, bulging eyes, and pulsating headaches. In these cases, fixing the vascular problem treats the glaucoma.
Glaucoma Drops and Stroke Risk
For patients who already have both glaucoma and elevated stroke risk, there is a practical medication concern. Topical beta-blocker eye drops, one of the oldest and most widely used classes of glaucoma medication, are absorbed into the bloodstream through the tear ducts and nasal mucosa. A large retrospective study found that patients using topical beta-blocker eye drops for glaucoma had a modestly higher rate of ischemic stroke compared to patients using other glaucoma medications, though when age and sex interactions were accounted for, the association lost statistical significance.16PubMed. Association between topical beta-blockers and risks of cardiovascular and respiratory disease in patients with glaucoma: a retrospective cohort study
The evidence here is not strong enough to say beta-blocker eye drops cause strokes. But for a glaucoma patient who has already had a stroke or has significant cardiovascular risk factors, the choice of eye drop may warrant a conversation. Several effective alternatives exist, including prostaglandin analogs, which are now more commonly used as first-line treatment and do not carry cardiovascular concerns.
When Glaucoma Surgery Meets Anticoagulation
Stroke survivors often take blood thinners long-term to prevent another event. This creates a practical dilemma if they later need glaucoma surgery. Many glaucoma procedures involve delicate tissue manipulation where bleeding can compromise the outcome. The question of whether to pause anticoagulation before surgery has no clean answer. A review of the available evidence found that it remains unclear whether stopping blood thinners before glaucoma surgery improves outcomes, and given the serious risks of pausing anticoagulation in stroke patients, any changes should be made cautiously and in coordination with the prescribing physician.17PubMed. Anticoagulation in Glaucoma Surgery
In practice, many surgeons now favor minimally invasive glaucoma surgery techniques that involve less tissue disruption and lower bleeding risk, which can sometimes allow patients to stay on their blood thinners. But each case requires balancing the stroke prevention benefit against the surgical complication risk.
The Optic Nerve’s Own Waste Clearance System
A newer area of research is exploring how the eye clears metabolic waste, and how ischemia disrupts that process. The brain has a waste-removal system that uses fluid flowing along blood vessels to flush out cellular debris during sleep. Recent work has shown that the optic nerve has a similar active clearance system. When researchers induced ischemia by blocking a carotid artery in animal models, they found that fluid accumulated abnormally in the optic nerve and the eye’s ability to clear waste was impaired.18PubMed. Optic nerve glymphatic system: Physiological characterization, ischemia-induced changes, and neuroprotection in ischemic optic neuropathy
This is still early-stage science, but it opens an intriguing possibility: that part of the damage in both stroke and glaucoma comes not just from lack of blood flow, but from the buildup of toxic byproducts that can no longer be flushed away. If that mechanism proves important, treatments that enhance waste clearance could potentially benefit both conditions.
Neuroprotection Research Spanning Both Diseases
Glaucoma and stroke both involve the death of neurons, whether retinal ganglion cells in the eye or brain cells in the cortex. Researchers have noted that many of the same protective strategies that show promise in one disease also work in the other. Neurotrophic factors, antioxidants, and certain enzyme inhibitors have demonstrated similar efficacy across neurodegenerative diseases affecting both the eye and the brain, supporting the idea that the downstream damage pathways are shared regardless of what triggered the initial injury.19Frontiers in Neurology. Neuroprotection in neurodegenerations of the brain and eye: Lessons from the past and directions for the future
No neuroprotective drug has yet been approved specifically for glaucoma, and the track record in stroke treatment is similarly disappointing despite decades of effort. But the overlap means that a breakthrough in one field could translate quickly to the other. Clinical trials targeting shared molecular pathways are ongoing, and the eye’s accessibility for imaging and drug delivery makes it an appealing testing ground for therapies that might eventually be used in the brain as well.